Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.
AUTOR(ES)
Fletcher, M R
RESUMO
Two studies are reported; a double-blind cross-over trial of feprazone 600 mg daily and aspirin 3.6 g daily in the treatment of rheumatoid arthritis, and an uncontrolled open study of gastrointestinal tolerance in twenty rheumatoid arthritis patients with known intolerance to other drugs. The first study showed that feprazone was significantly superior to aspirin in all the parameters tested. In the second study all twenty patients showed an improvement of their gastrointestinal symptoms, nineteen reporting no symptoms at all when taking the new preparation.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1006371Documentos Relacionados
- Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis.
- Toward a new anti-inflammatory and analgesic agent
- Gastrointestinal complications of nonsteroidal anti-inflammatory drugs.
- Sulindac. Trials of a new anti-inflammatory drug.
- New Perspectives in Anti-Inflammatory Therapies
